{
    "clinical_study": {
        "@rank": "146154", 
        "arm_group": {
            "arm_group_label": "Ulthera System Treatment", 
            "arm_group_type": "Experimental", 
            "description": "Ulthera System treatment of the decolletage"
        }, 
        "brief_summary": {
            "textblock": "This is prospective, multi-center clinical trial.  Enrolled subjects will receive one\n      Ulthera\u00ae treatment on the decolletage. Follow-up visits will occur at 90 and 180 days\n      following treatment. Study images will be obtained pre-treatment, immediately\n      post-treatment, and at each follow-up visit."
        }, 
        "brief_title": "Evaluation of the Ulthera System for the Treatment of the Decolletage", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Chest Wrinkles", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female, aged 35 to 70 years.\n\n          -  Subject in good health.\n\n          -  Moderate to severe skin lines and wrinkles on the d\u00e9colletage; grade of \u22654 on a chest\n             wrinkle scale.\n\n          -  Understands and accepts the obligation not to undergo any other procedures in the\n             areas to be treated through the follow-up period.\n\n          -  Willingness and ability to comply with protocol requirements.\n\n          -  Subjects of childbearing potential must have a negative urine pregnancy test result\n             and must not be lactating.\n\n          -  Absence of physical conditions unacceptable to the investigator.\n\n          -  Willingness and ability to provide written consent for study-required photography.\n\n          -  Willingness and ability to provide written informed consent.\n\n        Exclusion Criteria:\n\n          -  Presence of an active systemic or local skin disease that may affect wound healing.\n\n          -  Scarring in areas to be treated.\n\n          -  Tattoos in the areas to be treated.\n\n          -  Patients with ports or defibrillators.\n\n          -  Any open wounds or lesions in the area.\n\n          -  Active and severe inflammatory acne in the region to be treated.\n\n          -  Patients who have a history with keloid formation or hypertrophic scarring.\n\n          -  Inability to understand the protocol or to give informed consent.\n\n          -  Retinoid, microdermabrasion, or prescription level glycolic acid treatments to the\n             d\u00e9colletage area within two weeks prior to study participation or during the study.\n\n          -  Marked d\u00e9colletage asymmetry, ptosis, excessive dermatochalasis, deep dermal\n             scarring, or thick sebaceous skin.\n\n          -  History of chronic drug or alcohol abuse.\n\n          -  History of autoimmune disease.\n\n          -  Concurrent therapy that would interfere with the evaluation of the safety or\n             effectiveness of the study device.\n\n          -  Subjects who anticipate the need for surgery or overnight hospitalization during the\n             study.\n\n          -  Subjects who have a history of poor cooperation, noncompliance with medical\n             treatment, or unreliability.\n\n          -  Concurrent enrollment in any study involving the use of investigational devices or\n             drugs.\n\n          -  Current smoker or history of smoking in the last one year.\n\n          -  History of using the following prescription medications:\n\n               1. Topical Retinoids to the area within the past two weeks;\n\n               2. Antiplatelet agents/anticoagulants (Coumadin, Heparin, Plavix).\n\n               3. Psychiatric drugs that would impair the subject from understanding the protocol\n                  requirements or understanding and signing the informed consent."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "130", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "October 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01713686", 
            "org_study_id": "ULT-129"
        }, 
        "intervention": {
            "arm_group_label": "Ulthera System Treatment", 
            "description": "Focused ultrasound energy delivered below the surface of the skin", 
            "intervention_name": "Ulthera System Treatment", 
            "intervention_type": "Device", 
            "other_name": "Ultherapy\u2122"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Ulthera\u00ae System", 
            "Ultherapy\u2122 Treatment", 
            "Ulthera, Inc.", 
            "Micro-focused Ultrasound with Visualization (MFU-V)"
        ], 
        "lastchanged_date": "September 9, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sacremento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95816"
                    }, 
                    "name": "Laser Skin and Surgery Center of Northern California"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "92121"
                    }, 
                    "name": "Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60611"
                    }, 
                    "name": "Denova Research"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37215"
                    }, 
                    "name": "Tennessee Research Center"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Prospective, Multi-center, Pivotal Trial Evaluating the Safety and Effectiveness of the Ulthera\u00ae System for Improvement in Lines and Wrinkles of the D\u00e9colletage", 
        "overall_official": {
            "affiliation": "Dermatology Cosmetic Laser Medical  Associates of La Jolla, Inc.", 
            "last_name": "Mitchel P Goldman, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Assessment of improvement, in a blinded fashion, using a Chest Wrinkle Scale at 180 days post-treatment", 
            "measure": "Number of Participants with a Reduction in Chest Wrinkles at 180 days Post Treatment", 
            "safety_issue": "No", 
            "time_frame": "180 days post treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01713686"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall aesthetic improvement at each post treatment study visit will be compared to baseline will be assessed using the Global Aesthetic Improvement Scale (GAIS).", 
                "measure": "Overall Aesthetic Improvement", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed to 180 days post-treatment"
            }, 
            {
                "description": "Subject satisfaction will be measured at each follow-up visit using a Patient Satisfaction Questionnaire.", 
                "measure": "Subject Satisfaction", 
                "safety_issue": "No", 
                "time_frame": "Participants will be followed to180 days post-treatment"
            }, 
            {
                "description": "Assessment of improvement, in a blinded fashion, using a Chest Wrinkle Scale at 90 days post-treatment", 
                "measure": "Number of Participants with a Reduction in Chest Wrinkles at 90 days Post Treatment", 
                "safety_issue": "No", 
                "time_frame": "90 days post-treatment"
            }
        ], 
        "source": "Ulthera, Inc", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ulthera, Inc", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}